Your browser doesn't support javascript.
loading
Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months.
Luckhoff, H; Phahladira, L; Scheffler, F; Asmal, L; du Plessis, S; Chiliza, B; Kilian, S; Emsley, R.
Afiliação
  • Luckhoff H; Department of Psychiatry, Stellenbosch University, South Africa. Electronic address: hilmarklausl@gmail.com.
  • Phahladira L; Department of Psychiatry, Stellenbosch University, South Africa.
  • Scheffler F; Department of Psychiatry, Stellenbosch University, South Africa.
  • Asmal L; Department of Psychiatry, Stellenbosch University, South Africa.
  • du Plessis S; Department of Psychiatry, Stellenbosch University, South Africa.
  • Chiliza B; Department of Psychiatry, Nelson R Mandela School of Medicine, University of Kwazulu-Natal, South Africa.
  • Kilian S; Department of Psychiatry, Stellenbosch University, South Africa.
  • Emsley R; Department of Psychiatry, Stellenbosch University, South Africa.
Schizophr Res ; 206: 171-176, 2019 04.
Article em En | MEDLINE | ID: mdl-30503765
BACKGROUND: Treatment-emergent weight gain is associated with antipsychotic efficacy in schizophrenia patients treated with clozapine and olanzapine. However, few studies have investigated this relationship in first-episode patients treated with other antipsychotics, in particular those with a lower obesogenic potential. Aim To investigate the relationships between weight gain and associated metabolic changes with psychopathology improvement in relation to age, sex, ethnicity, substance use, treatment duration and antipsychotic dose in first-episode schizophrenia spectrum disorder patients. METHODS: This single site cohort study included 106 minimally treated or antipsychotic-naive patients treated with flupenthixol decanoate over 12 months. Psychopathology was evaluated using the Positive and Negative Syndrome Scale (PANSS) and BMI, fasting blood lipids and glucose were assessed at regular intervals. Linear regression models were constructed to determine the effects of socio-demographic, clinical and metabolic factors as predictors of change in total PANSS score and factor-derived domains. RESULTS: BMI change scores were inversely correlated with change in PANSS total (R = -0.25; p = 0.011), positive (R = -0.23; p = 0.019), depressive anxiety (R = -0.21; p = 0.031) and disorganized symptoms (R = -0.32; p < 0.001). Linear regression analysis showed that increased BMI and treatment duration both predicted improvement in global psychopathology and disorganized symptoms independent of age, sex, ethnicity, substance use, co-medication with antidepressants and/or anticholinergics, as well as the dose and duration of antipsychotic exposure. CONCLUSIONS: Our findings suggest that the relationship between treatment-emergent weight gain and psychopathology improvement is not limited to patients treated with antipsychotics most associated with weight gain, and is not confounded by treatment duration and dose.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Aumento de Peso / Avaliação de Resultados em Cuidados de Saúde / Antagonistas de Dopamina Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Aumento de Peso / Avaliação de Resultados em Cuidados de Saúde / Antagonistas de Dopamina Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article